LifeVantage Corporation
LFVNConsumer DefensiveNASDAQPackaged Foods · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the consumer defensive sector, LifeVantage Corporation focuses on Packaged Foods services and products. LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut. The company carries a $73.8M market cap, placing it firmly in the micro-cap category. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and.
Market Cap
$73.8M
Beta
0.71
P/E (TTM)
15.03
P/E (Fwd)
15.15
EPS (TTM)
$0.39
EPS (Fwd)
$0.39
ROE
14.9%
ROA
6.3%
Cash
$14.9M
Total Debt
$9.9M
Free CF
$6.0M
52W Change
-32.4%
Annual Financials
Cash vs Debt
Where LFVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LFVN finished 0.66% below its 150-day moving average ($6.02) and 2.40% above its 200-day moving average ($5.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFVN overbought or oversold?
At the October 20, 2026 close, LFVN's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $14.9M in cash comfortably exceeding the $9.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $6.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 14.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $213.4M (2023) to $182.6M (2026), a 14% decline worth watching.
As with any equity investment, LFVN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LifeVantage Corporation's trajectory.